← FDA Drug Approvals (Drugs@FDA)
REGADENOSON
ANDA · Abbreviated New Drug Application (Generic) · Sponsor: HOSPIRA · Approved 2022-08-31
Drug application
- FDA Application #
ANDA214349- Application type
- Abbreviated New Drug Application (Generic)
- Brand name
- REGADENOSON
- Generic name
- REGADENOSON
- Active ingredients
- REGADENOSON
- Dosage form
- SOLUTION
- Route
- INTRAVENOUS
- Marketing status
- Prescription
- Sponsor
- HOSPIRA
- Manufacturer
- Hospira, Inc.
- First approval
- 2022-08-31
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown